13.00

2.77% -0.35

Wave Life Sciences Ltd (WVE)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt WVE? Forum Prognose

Schlusskurs vom Vortag:

$13.35

Offen:

$13.42

24-Stunden-Volumen:

1.92M

Relative Volume:

0.30

Marktkapitalisierung:

$2.45B

Einnahmen:

$42.73M

Nettoeinkommen (Verlust:

$-204.38M

KGV:

-10.72

EPS:

-1.2124

Netto-Cashflow:

$-189.73M

1W Leistung:

-1.07%

1M Leistung:

+2.37%

6M Leistung:

+86.23%

1J Leistung:

+26.39%

1-Tages-Spanne:

$12.58

$13.65

1-Wochen-Bereich:

$12.58

$14.32

52-Wochen-Spanne:

$5.28

$21.73

Wave Life Sciences Ltd Stock (WVE) Company Profile

Firmenname

Wave Life Sciences Ltd

Sektor

Healthcare (1118)

Branche

Biotechnology (616)

Telefon

617-949-2900

Adresse

7 STRAITS VIEW, SINGAPORE

Mitarbeiter

317

Twitter

@WAVELifeSci

Nächster Verdiensttermin

2025-03-04

Neueste SEC-Einreichungen

WVE's Discussions on Twitter

Compare WVE vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
WVE Wave Life Sciences Ltd	13.00	2.51B	42.73M	-204.38M	-189.73M	-1.2124
VRTX Vertex Pharmaceuticals Inc	472.45	121.46B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	743.82	78.93B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	702.75	43.87B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	313.81	42.07B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	283.80	31.65B	5.36B	287.73M	924.18M	2.5229

Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-02-05	Eingeleitet	BofA Securities	Buy
2025-12-12	Bestätigt	Wedbush	Outperform
2025-12-09	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2025-10-20	Eingeleitet	Wells Fargo	Overweight
2025-08-04	Eingeleitet	Canaccord Genuity	Buy
2025-07-28	Eingeleitet	Oppenheimer	Outperform
2025-07-16	Eingeleitet	Citigroup	Buy
2025-06-11	Fortgesetzt	Raymond James	Outperform
2025-04-29	Eingeleitet	Cantor Fitzgerald	Overweight
2025-04-08	Eingeleitet	Wedbush	Outperform
2025-02-25	Eingeleitet	Jefferies	Buy
2024-10-16	Hochstufung	Raymond James	Outperform → Strong Buy
2024-09-27	Fortgesetzt	JP Morgan	Overweight
2024-09-19	Eingeleitet	B. Riley Securities	Buy
2024-09-09	Eingeleitet	JP Morgan	Overweight
2024-05-15	Eingeleitet	Wells Fargo	Overweight
2023-12-19	Hochstufung	Leerink Partners	Market Perform → Outperform
2023-07-05	Eingeleitet	Raymond James	Outperform
2023-05-24	Herabstufung	Jefferies	Buy → Hold
2020-12-15	Fortgesetzt	H.C. Wainwright	Buy
2020-10-23	Eingeleitet	RBC Capital Mkts	Sector Perform
2019-12-31	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2019-11-01	Eingeleitet	Guggenheim	Buy
2019-07-15	Eingeleitet	Cowen	Market Perform
2019-04-17	Bestätigt	H.C. Wainwright	Buy
2018-08-07	Eingeleitet	Stifel	Buy
2018-07-23	Eingeleitet	H.C. Wainwright	Buy
2018-03-19	Bestätigt	Mizuho	Buy
2017-02-15	Eingeleitet	H.C. Wainwright	Buy
2016-11-10	Fortgesetzt	Leerink Partners	Outperform
2015-12-07	Eingeleitet	JMP Securities	Mkt Outperform
2015-12-07	Eingeleitet	Jefferies	Buy
2015-12-07	Eingeleitet	Leerink Partners	Outperform
2015-12-07	Eingeleitet	Sun Trust Rbsn Humphrey	Buy

Alle ansehen

Wave Life Sciences Ltd Aktie (WVE) Neueste Nachrichten

Mar 12, 2026

Discipline and Rules-Based Execution in WVE Response - Stock Traders Daily

Mar 12, 2026

Mar 11, 2026

Dynamic SXSW panel reshapes obesity treatment narrative, WAVE Life Sciences asserts - Traders Union

Mar 11, 2026

Mar 10, 2026

Canaccord Genuity Boosts Price Target for WAVE Life Sciences (WV - GuruFocus

Mar 10, 2026

WAVE Life Sciences Stock: A Deep Dive Into Analyst Perspectives (11 Ratings) - Benzinga

Mar 10, 2026

WAVE Life Sciences (NASDAQ:WVE) Given New $52.00 Price Target at Canaccord Genuity Group - MarketBeat

Mar 10, 2026

Mar 09, 2026

Wave Life Sciences to present WVE-006 trial data at ATS - Investing.com Nigeria

Mar 09, 2026

Mar 08, 2026

Wave Life Sciences (WVE) Is Down 5.8% After Wider Losses And WVE-006 Accelerated Approval PushWhat's Changed - simplywall.st

Mar 08, 2026

Mar 07, 2026

Wave Life Sciences (WVE) Valuation Check After New RNA Editing And Obesity Trial Updates - simplywall.st

Mar 06, 2026

Wedbush Forecasts Strong Price Appreciation for WAVE Life Sciences (NASDAQ:WVE) Stock - MarketBeat

Mar 06, 2026

Wave Life Sciences (WVE) Anticipates Positive Developments with WVE-007 Data - GuruFocus

Mar 06, 2026

Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference - Sahm

Mar 06, 2026

Wave Life Sciences to present WVE-006 trial data at ATS By Investing.com - Investing.com Canada

Mar 06, 2026

Mar 05, 2026

Wave Life Sciences announces acceptance of late-breaking oral presentation on Wve-006 for alpha-1 antitrypsin deficiency at the American Thoracic Society international conference - marketscreener.com

Mar 05, 2026

Q1 EPS Forecast for WAVE Life Sciences Raised by Analyst - MarketBeat

Mar 05, 2026

Mar 04, 2026

FY2029 Earnings Forecast for WVE Issued By HC Wainwright - MarketBeat

Mar 04, 2026

Mar 03, 2026

Wave Life Sciences Obesity Proof Of Concept Sparks Focus On Pipeline Upside - simplywall.st

Mar 03, 2026

WVE SEC FilingsWave Life Scienc 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 03, 2026